Institut_Pharmazie

Prof. Dr. Monika Schäfer-Korting

MSK

Institut für Pharmazie

Professorin

Aufgabenbereich

Pharmakologie und Toxikologie

Adresse Freie Universität Berlin
Institut für Pharmazie
Königin-Luise-Str. 2+4
Raum VH 171
14195 Berlin
Sekretariat
Telefon +4930 838-53283
Fax +4930 838-470871
E-Mail monika.schaefer-korting@fu-berlin.de
Homepage Prof. Dr. Monika Schäfer-Korting
1971-1975 Studium der Pharmazie an der Goethe-Universität Frankfurt
1976 Approbation als Apotheker
1977 Promotion
1989 Habilitation
1994 Berufung auf den neueingerichteten Pharmakologie-Lehrstuhl am Fachbereich Pharmazie der Freien Universität Berlin
seit 1995 Beirat des Verbandes der Professoren an Pharmazeutischen Hochschulinstituten der Bundesrepublik Deutschland

Vorstand der Gesellschaft für Dermopharmazie
1997-99 Vizepräsidentin der Freien Universität Berlin
seit 2000 Wissenschaftliche Leitung der ScienceFair Berlin
2001-2005 Prodekanin des Fachbereichs Biologie, Chemie, Pharmazie, FUB
2002-2008

Sprecherin der DFG-Forschergruppe "Innovative Arzneistoffe und Trägersysteme - Integrative Optimierung zur Behandlung entzündlicher und hyperproliferativer Erkrankungen" (FG 463)

Koordinatorin der BMBF-Verbundprojekts: "Validierungsstudie zur Prüfung auf Hautpenetration mit Hilfe von biotechnologisch hergestellten Hautmodellen" (FKZ 0312881)

seit 2005 Mitglied/Vorsitzende des Wissenschaftlichen Beirats des Bundesinstituts für Risikobewertung, Berlin
2006 - (2010) Mitglied des BMBF-geförderten Forschungsverbunds „NanoDerm“
seit 2007 Vizepräsidentin der Freien Universität Berlin
seit 2009 Mitglied des BMBF-Verbundprojekts "Hautmetabolismus"
seit 2010 Mitglied der EU-Koordinierungsgruppe “Accelerating the transition to a toxicity pathway-based paradigm for chemical safety assessment” (AXLR8)
seit 2012 Mitglied des Helmholtz Virtuellen Instituts “Funktionelle Biomaterialien für die Medizin”

Scientific Curriculum

1976-1977

Ph.D. thesis, Pharmakologisches Institut für Naturwissenschaftler, Goethe-Universität Frankfurt/M (Germany) with Prof. Dr. Dr. E. Mutschler

1978-79

Postdoctoral Fellow Institut für Pharmakologie und Toxikologie, Technische Universität München with Prof. Dr. M. Reiter

1980-92

Research associate at the Pharmakologisches Institut für Naturwissenschaftler, Goethe-Universität Frankfurt/M (Germany) with Prof. Dr. Dr. E. Mutschler

1992-94

Guest professor at the Institut für Pharmazie, Freie Universität Berlin

since 1994

Full professor of Pharmacology at the Institut für Pharmazie, Freie Universität Berlin

1997-1999

Vice-President of the Freie Universität Berlin

2003

Elected Vice-President for Research of the University of Veterinary Medicine, Vienna (Austria; declined)

2003-2008

Speaker of the DFG research group 463 “Innovative drugs and carrier systems”

since 2004

Board Member of the Ethics Committee of the University of Veterinary Medicine, Vienna (Austria)

since 2004

Training Laboratory for Alternatives to Experiments in the Animal (EFRE funding)

since 2005

Head of the Scientific Advisory Board of the Federal Institute for Risk Assessment, Berlin (Germany)

2006-2010

Member of the BMBF research group “NanoDerm”

since 2007

Vice-President of the Freie Universität Berlin (Biosciences and Research)

2009-2011 Member of the BMBF research group “Skin Metabolism”

2010 (-2013)

Member of the EU Coordination group “Accelerating the transition to a toxicity pathway-based paradigm for chemical safety assessment” (AXLR8)

since 2012

Member of Helmholtz Viritual Institute “Functional Biomaterials for Medicine”

Forschungsschwerpunkte

Im Zentrum steht die Verbesserung der Therapie von Hauterkrankungen durch Prüfung potentieller neuer Pharmaka mit Wirkung auf die Haut, Aufklärung der molekularen Wirkmechanismen bekannter und neuer Wirkstoffe, Untersuchung der Aufnahme und Metabolisierung solcher Substanzen in Humanhaut, aber auch mit Hilfe von zwei- und dreidimensionalen Hautmodellen sowie Modellen von Hautkrankheiten und eine Steigerung der Nutzen/Risiko-Relation mittels partikulärer Trägersysteme.

Pharmakokinetische Experimente zeigen darüber hinaus einen wesentlichen Beitrag der Metabolisierung dieser Pharmaka in der Haut für die Unterschiede in der Nutzen/Risiko-Relation. Gerade diese Untersuchungen weisen auf die besondere Bedeutung des heute noch weithin unbekannten Hautmetabolismus hin.

Nachdem bereits klinische Untersuchungen mit einem liposomalen Glucocorticoid auf einen Fortschritt durch partikuläre Trägersysteme hingewiesen haben, erfolgen nun systematische Untersuchungen zur hautspezifischen Wirkstoffapplikation mit Hilfe komplexer Trägersysteme. 

 

Monographien

  • Korting H.C., Schäfer-Korting M. (Hrsg.) The Benefit/Risk ratio: A Handbook of the Rational use of Potentially Hazardous Drugs. CRC Press, Boca Raton (1999)
  • Mutschler, Schäfer-Korting M. "Arzneimittelwirkungen", 7. Aufl., Wissenschaftliche Verlagsgesellschaft Stuttgart (1996)
  • Mutschler "Arzneimittelwirkungen" 8. Aufl., 2001
  • Mutschler "Arzneimittelwirkungen" 9. Aufl., 2009
  • Mutschler "Arzneimittelwirkungen kompakt", 2005
  • Optimierte Arzneimitteltherapie (Reihenherausgeber), Springer-Verlag, Heidelberg:
    Ruzicka T, Schürer N: Ekzeme (1999)
    Diener HC: Migräne (1999)
    Soyka M: Alkoholabhängigkeit (1999)
    Sökeland J, Zwergel U: Benigne Prostatahyperplasie (1999)
    Dannhardt G. Rheumatische Erkrankungen (1999)
    Seebacher C: Dermatomykosen (2001)

Originalarbeiten

  • Charbaji N, Schäfer-Korting M, Küchler S (2012) Morphine stimulates cell migration of oral epithelial cells by delta-opioid receptor activation. PLoS One 7: e42616
  • Heilmann S, Küchler S, Schäfer-Korting M (2012) Morphine Metabolism in Human Skin Microsomes. Skin Pharmacol Physiol 25: 319-322
  • Korting HC, Schöllmann C, Stauss-Grabo M, Schäfer-Korting M (2012) Antimicrobial Peptides and Skin: A Paradigm of Translational Medicine.Skin Pharmacol Physiol 25: 323-334
  • Küchler S, Henkes D, Eckl KM, Ackermann K, Plendl J, Korting HC, Hennies HC, Schäfer-Korting M (2011) Hallmarks of Atopic Skin Mimicked In Vitro by Means of a Skin Disease Model Based on FLG Knock-down. Altern Lab Anim 39: 471-480
  • Haag SF, Taskoparan B, Bittl R, Teutloff C, Wenzel R, Fahr A, Chen M, Lademann J, Schäfer-Korting M, Meinke MC (2011c) Stabilization of reactive nitroxides using invasomes to allow prolonged electron paramagnetic resonance measurements. Skin Pharmacol Physiol 24: 312-321
  • Haag SF, Fleige E, Chen M, Fahr A, Teutloff C, Bittl R, Lademann J, Schäfer-Korting M, Haag R, Meinke MC (2011b) Skin penetration enhancement of core-multishell nanotransporters and invasomes measured by electron paramagnetic resonance spectroscopy. Int J Pharm 416: 223-228
  • Zdrazil, B., Schwanke, A., Schmitz, B., Schäfer-Korting, M. and Höltje, H. D. (2011) Molecular modelling studies of new potential human DNA polymerase alpha inhibitors. J Enzyme Inhib Med Chem, 26, 270-279.
  • Schlupp, P., Blaschke, T., Kramer, K. D., Höltje, H. D., Mehnert, W. and Schäfer-Korting, M. (2011) Drug Release and Skin Penetration from Solid Lipid Nanoparticles and a Base Cream: A Systematic Approach from a Comparison of Three Glucocorticoids. Skin Pharmacol Physiol, 24, 199-209.
  • Semlin, L., Schäfer-Korting, M., Borelli, C. and Korting, H. C. (2011) In vitro models for human skin disease. Drug Discov Today, 16, 132-139.
  • J. Sendzik, M. Shakibaei, M. Schäfer-Korting, H. Lode, and R. Stahlmann. Synergistic effects of dexamethasone and quinolones on human-derived tendon cells. Int J Antimicrob Agents. 35:366-374 (2010).
  • M. Schäfer-Korting, M. Höltje, H.C. Korting, and H.D. Höltje. Innovative agents for actinic keratosis and nanocarriers enhancing skin penetration. Skin Pharmacol Physiol. 23:6-14 (2010).
  • S. Küchler, N.B. Wolf, S. Heilmann, G. Weindl, J. Helfmann, M.M. Yahya, C. Stein, and M. Schäfer-Korting. 3D-Wound healing model: Influence of morphine and solid lipid nanoparticles. J Biotechnol. DOI: S0168-1656(10)00028-3 [pii] (2010).
  • S. Küchler, W. Herrmann, G. Panek-Minkin, T. Blaschke, C. Zoschke, K.D. Kramer, R. Bittl, and M. Schäfer-Korting. SLN for topical application in skin diseases-Characterization of drug-carrier and carrier-target interactions. Int J Pharm. DOI: S0378-5173(10)00099-2 [pii] (2010).
  • H.C. Korting and M. Schäfer-Korting. Carriers in the topical treatment of skin disease. Handb Exp Pharmacol:435-468 (2010).
  • M. Höltje, A. Richartz, B. Zdrazil, A. Schwanke, B. Dugovic, C. Murruzzu, H.U. Reissig, H.C. Korting, B. Kleuser, H.D. Höltje, and M. Schäfer-Korting. Human polymerase alpha inhibitors for skin tumors. Part 2. Modeling, synthesis and influence on normal and transformed keratinocytes of new thymidine and purine derivatives. J Enzyme Inhib Med Chem. 25:250-265 (2010).
  • K. Ackermann, S.L. Borgia, H.C. Korting, K.R. Mewes, and M. Schafer-Korting. The Phenion full-thickness skin model for percutaneous absorption testing. Skin Pharmacol Physiol. 23:105-112 (2010).
  • S. Küchler, M. Abdel-Mottaleb, A. Lamprecht, M.R. Radowski, R. Haag, and M. Schäfer-Korting. Influence of nanocarrier type and size on skin delivery of hydrophilic agents. Int J Pharm. 377:169-172 (2009).
  • A.K. Manzer, S. Lombardi-Borgia, M. Schäfer-Korting, J. Seeber, M. Zorn-Kruppa, and M. Engelke. SV40-Transformed Human Corneal Keratocytes: Optimisation of Serum-free Culture Conditions. ALTEX. 26:33-39 (2009).
  • B. Nieuwenhuis, A. Lüth, J. Chun, A. Huwiler, J. Pfeilschifter, M. Schäfer-Korting, and B. Kleuser. Involvement of the ABC-transporter ABCC1 and the sphingosine 1-phosphate receptor subtype S1P(3) in the cytoprotection of human fibroblasts by the glucocorticoid dexamethasone. J Mol Med 87:645-57 (2009).
  • N.B. Wolf, S. Küchler, M.R. Radowski, T. Blaschke, K.D. Kramer, G. Weindl, B. Kleuser, R. Haag, and M. Schäfer-Korting. Influences of opioids and nanoparticles on in vitro wound healing models. Eur J Pharm Biopharm http://www.sciencedirect.com/scidirimg/clear.gifdoi:10.1016/j.ejpb.2009.03.009 (2009).
  • Küchler S, Radowski MR, Blaschke T, Dathe M, Plendl J, Haag R, Schäfer-Korting M, Kramer KD: Nanoparticles for skin penetration enhancement--a comparison of a dendritic core-multishell-nanotransporter and solid lipid nanoparticles. Eur J Pharm Biopharm 2009; 71:243-250.
  • J.W. Seeber, M. Zorn-Kruppa, S. Lomardi-Borgia, H. Scholz, A.K. Manzer, B. Rusche, M. Schäfer-Korting, M. Engelke, Characterisation of human corneal epithelial cell cultures maintained under serum-free conditions. Altern Lab Anim 36 (2008) 569-583
  • M. Schüppel, U. Kürschner, U. Kleuser, M. Schäfer-Korting, B. Kleuser, Sphingosine 1-Phosphate Restrains Insulin-Mediated Keratinocyte Proliferation via Inhibition of Akt through the S1P(2) Receptor Subtype. J Invest Dermatol (2008).
  • M. Schäfer-Korting, C. Schoellmann, H.C. Korting, Fungicidal activity plus reservoir effect allow short treatment courses with terbinafine in tinea pedis. Skin Pharmacol Physiol 21 (2008) 203-210.
  • M. Schäfer-Korting, A. Mahmoud, S. Lombardi Borgia, B. Brüggener, B. Kleuser, S. Schreiber, W. Mehnert, Reconstructed epidermis and full-thickness skin for absorption testing: influence of the vehicles used on steroid permeation. Altern Lab Anim 36 (2008) 441-452.
  • M. Schäfer-Korting, U. Bock, W. Diembeck, H.J. Dusing, A. Gamer, E. Haltner-Ukomadu, C. Hoffmann, M. Kaca, H. Kamp, S. Kersen, M. Kietzmann, H.C. Korting, H.U. Krächter, C.M. Lehr, M. Liebsch, A. Mehling, C. Müller-Goymann, F. Netzlaff, F. Niedorf, M.K. Rübbelke, U. Schäfer, E. Schmidt, S. Schreiber, H. Spielmann, A. Vuia, M. Weimer, The use of reconstructed human epidermis for skin absorption testing: Results of the validation study. Altern Lab Anim 36 (2008) 161-187.
  • A. Richartz, M. Höltje, B. Brandt, M. Schäfer-Korting, H.D. Höltje, Targeting human DNA polymerase alpha for the inhibition of keratinocyte proliferation. Part 1. Homology model, active site architecture and ligand binding. J Enzyme Inhib Med Chem 23 (2008) 94-100.
  • S. Lombardi Borgia, P. Schlupp, W. Mehnert, M. Schäfer-Korting, In vitro skin absorption and drug release - A comparison of six commercial prednicarbate preparations for topical use. Eur J Pharm Biopharm 68 (2008) 380-389
  • Du Y, Melchert HU, Schäfer-Korting M: Use of oral contraceptives in germany: Prevalence, determinants and use-associated health correlates. Results of national health surveys from 1984 to 1999. Eur J Obstet Gynecol Reprod Biol 2007; 134:57-66.
  • Stecova, J., Mehnert, W., Blaschke, T., Kleuser, B., Sivaramakrishnan, R., Zouboulis, C.C., Seltmann, H., Korting, H.C., Kramer, K.D. and Schäfer-Korting, M. (2007) Cyproterone acetate loading to lipid nanoparticles for topical acne treatment: particle characterisation and skin uptake. Pharm Res, 24, 991-1000.
  • Lombardi Borgia, S., Schlupp, P., Mehnert, W. and Schäfer-Korting, M. (2007) In vitro skin absorption and drug release - A comparison of six commercial prednicarbate preparations for topical use. Eur J Pharm Biopharm.
  • Braem, C., Blaschke, T., Panek-Minkin, G., Herrmann, W., Schlupp, P., Paepenmuller, T., Müller-Goyman, C., Mehnert, W., Bittl, R., Schäfer-Korting, M. and Kramer, K.D. (2007) Interaction of drug molecules with carrier systems as studied by parelectric spectroscopy and electron spin resonance. J Control Release, 119, 128-135.
  • Keller, C.D., Rivera Gil, P., Tolle, M., van der Giet, M., Chun, J., Radeke, H.H., Schäfer-Korting, M. and Kleuser, B. (2007) Immunomodulator FTY720 induces myofibroblast differentiation via the lysophospholipid receptor S1P3 and Smad3 signaling. Am J Path, 170, 281-292.
  • Weindl G, Roeder A, Schäfer-Korting M, Schaller M, Korting HC (2006) Receptor-selective retinoids for psoriasis: focus on tazarotene. American journal of clinical dermatology 7(2): 85-97.
  • Sigle, H.C., Schäfer-Korting, M., Korting, H.C., Hube, B. and Niewerth, M. (2006) In vitro investigations on the mode of action of the hydroxypyridone antimycotics rilopirox and piroctone on Candida albicans. Mycoses, 49, 159-168.
  • Schäfer-Korting, M., Bock, U., Gamer, A., Haberland, A., Haltner-Ukomadu, E., Kaca, M., Kamp, H., Kietzmann, M., Korting, H.C., Krächter, H.U., Lehr, C.M., Liebsch, M., Mehling, A., Netzlaff, F., Niedorf, F., Rübbelke, M.K., Schäfer, U., Schmidt, E., Schreiber, S., Schröder, K.R., Spielmann, H. and Vuia, A. (2006) Reconstructed human epidermis for skin absorption testing: results of the German prevalidation study. Altern Lab Anim, 34, 283-294.
  • Haberland, A., Schreiber, S., Maia, C.S., Rübbelke, M.K., Schaller, M., Korting, H.C., Kleuser, B., Schimke, I. and Schäfer-Korting, M. (2006) The impact of skin viability on drug metabolism and permeation -- BSA toxicity on primary keratinocytes. Toxicol In Vitro, 20, 347-354.
  • Du Y, Melchert HU, Schäfer-Korting M: Hormone replacement therapy in germany: Determinants and possible health-related outcomes. Results of national health surveys from 1984 to 1999. Maturitas 2005; 52:223-234.
  • Schäfer-Korting M, Kleuser B, Ahmed M, Höltje HD, Korting HC: Glucocorticoids for human skin: new aspects of the mechanism of action. Skin Pharmacol Physiol 2005, 18:103-14.
  • Sauer B, Gonska H, Manggau M, Kim DS, Schraut C, Schäfer-Korting M, Kleuser B: Sphingosine 1-phosphate is involved in cytoprotective actions of calcitriol in human fibroblasts and enhances the intracellular Bcl-2/Bax rheostat. Pharmazie  2005, 60:298-304.
  • Roeder, A.; Schaller, M.; Schäfer-Korting, M.; Korting, H. C., Safety and efficacy of fluticasone propionate in the topical treatment of skin diseases. Skin Pharmacol Physiol 2005, 18, (1), 3-11.
  • Mahmoud, A.; Haberland, A.; Dürrfeld, M.; Heydeck, D.; Wagner, S.; Schäfer-Korting, M., Cutaneous estradiol permeation, penetration and metabolism in pig and man. Skin Pharmacol Physiol 2005, 18, (1), 27-35.
  • Münster, U.; Nakamura, C.; Haberland, A.; Jores, K.; Mehnert, W.; Rummel, S.; Schaller, M.; Korting, H. C.; Zouboulis Ch, C.; Blume-Peytavi, U.; Schäfer-Korting, M., RU 58841-myristate--prodrug development for topical treatment of acne and androgenetic alopecia. Pharmazie 2005, 60, (1), 8-12.
  • Xin C, Ren S, Kleuser B, Shabahang S, Eberhardt W, Radeke H, Schäfer-Korting M, Pfeilschifter J, Huwiler A: Sphingosine 1-phosphate cross-activates the Smad signaling cascade and mimics transforming growth factor-beta-induced cell responses. J Biol Chem 279:35255-62 (2004).
  • Wittekindt C, Böttger M, Höltje HD, Schäfer-Korting M, Cartier R, Haberland A: Integrin-specificity of the cyclic Arg-Gly-Asp motif and its role in integrin targeted gene transfer. Biotechnol Appl Biochem (2004).
  • Kim DS, Kim SY, Kleuser B, Schäfer-Korting M, Kim KH, Park KC: Sphingosine-1-phosphate inhibits human keratinocyte proliferation via Akt/protein kinase B inactivation. Cell Signal 2004;16(1):89-95.
  • Hammer S, Sauer B, Spika I, Schraut C, Kleuser B, Schäfer-Korting M: Glucocorticoids mediate differential anti-apoptotic effects in human fibroblasts and keratinocytes via sphingosine-1-phosphate formation. J Cell Biochem 2004;91(4):840-51.
  • Roeder A, Schaller M, Schäfer-Korting M, Korting HC: Tazarotene: therapeutic strategies in the treatment of psoriasis, acne and photoaging. Skin Pharmacol Physiol 2004;17(3):111-8.
  • Olah Z, Trier U, Sauer B, Schäfer-Korting M, Kleuser B: New chimera proteins for fluorescence correlation spectroscopy. Pharmazie 59:516-23 (2004).
  • Sauer B, Vogler R, Zimmermann K, Fujii M, Anzano MB, Schäfer-Korting M, Roberts AB, Kleuser B: Lysophosphatidic acid interacts with transforming growth factor-beta signaling to mediate keratinocyte growth arrest and chemotaxis. J Invest Dermatol 123:840-9 (2004).
  • Sauer B, Vogler R, von Wenckstern H, Fujii M, Anzano MB, Glick AB, Schäfer-Korting M, Roberts AB, Kleuser B: Involvement of Smad signaling in sphingosine 1-phosphate-mediated biological responses of keratinocytes. J Biol Chem 279:38471-9 (2004).
  • Sivaramakrishnan R, Nakamura C, Mehnert W, Korting HC, Kramer KD, Schäfer-Korting M: Glucocorticoid entrapment into lipid carriers - characterisation by parelectric spectroscopy and influence on dermal uptake. J Control Release 97:493-502 (2004).
  • Weindl G, Schaller M, Schäfer-Korting M, Korting HC: Hyaluronic acid in the treatment and prevention of skin diseases: molecular biological, pharmaceutical and clinical aspects. Skin Pharmacol Physiol 17:207-13 (2004).
  • Vogler, R., Sauer, B., Kim, D. S., Schäfer-Korting, M., and Kleuser, B. Sphingosine-1-phosphate and its potentially paradoxical effects on critical parameters of cutaneous wound healing. J Invest Dermatol, 120: 693-700, 2003.
  • Spika, I., Hammer, S., Kleuser, B., Korting, H. C., and Schäfer-Korting, M. Transcriptional activity of potent glucocorticoids: relevance of glucocorticoid receptor isoforms and drug metabolites. Skin Pharmacol Appl Skin Physiol, 16: 143-150, 2003.
  • Haberland, A., Santos Maia, C., Jores, K., Dürrfeld, M., Mehnert, W., Schimke, I., Christ, B., and Schäfer-Korting, M. Albumin effects on drug absorption and metabolism in reconstructed epidermis and excised pig skin. Altex, 20: 3-9, 2003.
  • Hammer S, Spika I, Sippl W, Jessen G, Kleuser B, Holtje HD, Schafer-Korting M: Glucocorticoid receptor interactions with glucocorticoids: evaluation by molecular modeling and functional analysis of glucocorticoid receptor mutants. Steroids. 68:329-39, 2003.
  • Schäfer-Korting M: Pharmacology at the Free University of Berlin. The presentation of a chair in pharmacology and toxicology at the Free University of Berlin. Med Monatsschr Pharm 26:186-7, 2003.
  • Schäfer-Korting M, Holzgrabe U: A silver lining on the horizon: new antimycotics. Pharm Unserer Zeit 32:154-6, 2003.
  • Korting HC, Unholzer A, Schäfer-Korting M, Tausch I, Gassmueller J, Nietsch KH: Different skin thinning potential of equipotent medium-strength glucocorticoids. Skin Pharmacol Appl Skin Physiol  15(2): 85-91 (2002).
  • Manggau M, Kim DS, Ruwisch L, et al. 1Alpha,25-dihydroxyvitamin D3 protects human keratinocytes from apoptosis by the formation of sphingosine-1-phosphate. J Invest Dermatol.  117(5): 1241-9 (2001)
  • Xu H, Frank J, Trier U, et al. Interaction of fluorescence labeled single-stranded DNA with hexameric DNA-helicase RepA: a photon and fluorescence correlation spectroscopy study. Biochemistry  40(24): 7211-8 (2001)
  • Ruwisch L, Schäfer-Korting M, Kleuser B. An improved high-performance liquid chromatographic method for the determination of sphingosine-1-phosphate in complex biological materials. Naunyn Schmiedebergs Arch Pharmacol  363(3): 358-63 (2001).
  • Lange K, Kleuser B, Gysler, A, Bader M, Maia C, Scheidereit C, Korting HC, Schäfer-Korting M: Cutaneous inflammation and proliferation in vitro: Differential effects and mode of action of topical glucocorticoids. Skin Pharmacol Appl Skin Physiol 13, 93-103 (2000)
  • Jenning V, Schäfer-Korting M, Müller RH; Gohla S: Vitamin A loaded solid lipid nanoparticles for topical application: Drug release properties. J. Contr. Rel. 66, 115-126 (2000)
  • Maia C, Mehnert W, Schäfer-Korting M: Solid lipid nanoparticles as drug carriers for topical glucocorticoids. Int. J. Pharm. 196, 165-167 (2000)
  • Trier U, Olah, Z, Kleuser B, Schäfer-Korting M: Fusion of the binding domain of Raf-1 kinase with green fluorescent protein for activated Ras detection by fluorescence correlation spectroscopy. Pharmazie 4, 263-268 (1999)
  • Schüler J, Frank, J, Trier U, Schäfer-Korting M, Saenger W: Interactions kinetics of tetramethylrhodamine transferrin with human transferrin receptor studied by fluorescence correlation spectroscopy. Biochemistry 38, 8402-8408 (1999)
  • Gysler A, Kleuser B, Sippl W, Lange K, Korting HC, Höltje HD, Schäfer-Korting M: Skin penetration and metabolism of topical glucocorticoids in reconstructed epidermis and in excised human skin. Pharm. Res. 16,1386-1391 (1999)
  • Kim DS, Korting HC, Schäfer-Korting M: Effects of growth factors on the proliferation of human keratinocytes and fibroblasts in vitro. Pharmazie 53, 51-57 (1998)
  • Schmidt R, Streit M, Kaiser R, Herzberg F, Schirner, M, Schramm K, Kaufmann Ch, Henneken M, Schäfer-Korting M, Thiel E, Kreuser ED: De novo expression of the a 5b 1-fibronectin receptor in HT29 colon-cancer cells reduces activity of C-SRC. Increase of C-SRC activity by attachment on fibronectin. Int J Cancer 76, 91-98 (1998)
  • Gysler A, Lange K, Korting HC, Schäfer-Korting M: Prednicarbate biotransformation in human foreskin keratinocytes and fibroblasts. Pharm Res 14 (6), 797-801 (1997)
  • Korting HC., Schäfer-Korting M, Zienicke H, Georgii A, Ollert M: Treatment of tinea unguium with medium and high doses of ultramicrosize griseofulvin compared with that with itraconazole. Antimicrob Agents Chemother 37, 2064-2068 (1993)
  • Schäfer-Korting M, Korting HC, Kerscher M, Lenhard S: Prednicarbate activity and benefit/risk ratio in relation to other topical glucocorticoids. Clin Pharmacol Ther 54, 448-456 (1993)

Übersichtsarbeiten

  • Schackert C, Korting HC, Schäfer-Korting M: Qualitative and quantitative assessment of the benefit/risk ratio of medium potent topical glucocorticoids in vitro and in vivo: characterisation of drugs with an increased benefit/risk ratio. BioDrugs 13, 267-277 (2000)
  • Holzgrabe U, Schäfer-Korting M: Antimycotics. Pharm Unserer Zeit 32:87, 2003.
  • Schäfer-Korting M, Korting HC: Bronchial asthma and inflammatory dermatoses. Topical glucocorticoid treatment. Pharm Unserer Zeit 32:306-13, 2003.
  • Schäfer-Korting, M., Mehnert, W. and Korting, H.C. (2007) Lipid nanoparticles for improved topical application of drugs for skin diseases. Adv Drug Deliv Rev. 59, 427-43